Sarepta Therapeutics, Inc. (SRPT) Earnings History
Annual and quarterly earnings data from 1995 to 2025
Loading earnings history...
SRPT EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
SRPT Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 59.9% | -29.9% | -32.5% |
| 2024 | 83.2% | 11.5% | 12.4% |
| 2023 | 87.9% | -21.5% | -43.1% |
| 2022 | 85.0% | -57.5% | -75.4% |
| 2021 | 86.2% | -65.5% | -59.7% |
Download Data
Export SRPT earnings history in CSV or JSON format
Free sign-in required to download data
Sarepta Therapeutics, Inc. (SRPT) Earnings Overview
As of May 6, 2026, Sarepta Therapeutics, Inc. (SRPT) reported trailing twelve-month net income of $65M, reflecting -404.7% year-over-year growth. The company earned $0.53 per diluted share over the past four quarters, with a net profit margin of -32.5%.
Looking at the long-term picture, SRPT's historical earnings data spans multiple years. The company achieved its highest annual net income of $235M in fiscal 2024.
Sarepta Therapeutics, Inc. maintains positive profitability with a gross margin of 59.9%, operating margin of -29.9%, and net margin of -32.5%. The company continues to generate positive earnings from operations. View revenue history →
Compared to peers including BMRN ($269M net income, 10.8% margin), ALNY ($577M net income, 8.4% margin), RARE (-$609M net income, -85.4% margin), SRPT has room to improve margins relative to the peer group. Compare SRPT vs BMRN →
SRPT Earnings vs Peers
Earnings metrics vs comparable public companies
SRPT Historical Earnings Data (1995–2025)
31 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$713M | -403.3% | -$658M | $-7.13 | -32.5% | -29.9% |
| 2024 | $235M | +143.9% | $218M | $2.34 | 12.4% | 11.5% |
| 2023 | -$536M | +23.8% | -$268M | $-5.80 | -43.1% | -21.5% |
| 2022 | -$703M | -68.0% | -$536M | $-8.03 | -75.4% | -57.5% |
| 2021 | -$419M | +24.4% | -$460M | $-5.15 | -59.7% | -65.5% |
| 2020 | -$554M | +22.5% | -$564M | $-7.11 | -102.6% | -104.5% |
| 2019 | -$715M | -97.6% | -$706M | $-9.71 | -187.8% | -185.3% |
| 2018 | -$362M | -614.0% | -$344M | $-5.46 | -120.2% | -114.1% |
| 2017 | -$51M | +81.0% | -$172M | $-0.86 | -32.8% | -111.0% |
| 2016 | -$267M | -21.5% | -$267M | $-5.49 | -4930.2% | -4920.3% |
See SRPT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SRPT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SRPT vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSRPT — Frequently Asked Questions
Quick answers to the most common questions about buying SRPT stock.
Is SRPT growing earnings?
SRPT EPS fell to $0.53, with earnings declining -404.7%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $65M.
What are SRPT's profit margins?
Sarepta Therapeutics, Inc. net margin is -32.5%, with operating margin at -29.9%. Below-average margins reflect competitive or cost pressures.
How consistent are SRPT's earnings?
SRPT earnings data spans 1995-2025. The declining earnings trend is -404.7% YoY. Historical data enables comparison across business cycles.